StockUS listing USIBOAMEXHealthcareCapital Destroyer

Impact BioMedical, Inc.(IBO) Stock Analysis | Healthcare

USD --+0.00%
Reward30Low
Risk78High
75%Data
Strong 4245% profit margin · Revenue growing 17% YoY
USD —+0.00 (+0.00%) Previous close · AMEX
Market cap 53.31M
Reward Ratingⓘ30 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ78 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on IBO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Impact BioMedical, Inc.?

discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.

AI Brief Pro

The brief on Impact BioMedical, Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Impact BioMedical, Inc.?

discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company is listed on the AMEX in USA, operating in the Healthcare sector, with a market capitalisation of 53.31M, and a P/E ratio of 0.5x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Low (30)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio0.4909
Beta2.892
Insider Activity
12M windowNo data
No insider activity data available for this ticker.